GENZYME CEREZYME RECOMBINANT GCR WILL BE AVAILABLE IN LIMITED QUANTITIES
Executive Summary
GENZYME CEREZYME RECOMBINANT GCR WILL BE AVAILABLE IN LIMITED QUANTITIES within the next month following its approval for Gaucher's disease on May 23, Genzyme announced May 24. Production of Cerezyme for the first year will be sufficient to treat approximately 120 Gaucher's disease patients. Patients eligible for treatment with Cerezyme will initially be limited to those participating in post-approval clinical trials who have not previously been treated with Ceredase. "The research has been designed in part to determine whether dosages can be lowered, thereby reducing the cost of therapy, without sacrificing effectiveness," Genzyme said.